APOPTONE

Related by string. Apoptone * * TRIOLEX HE# APOPTONE HE# . Apoptone HE# . APOPTONE TM HE# . APOPTONE ™ *

Related by context. All words. (Click for frequent words.) 72 PEG SN# 72 TRIOLEX 71 preclinically 71 OXi# 71 PXD# 71 antiangiogenic activity 70 Symadex 70 CTAP# Capsules 70 Apoptone 70 Triolex 69 GRNCM1 69 PSMA ADC 69 K ras mutations 69 iroxanadine 69 Azedra 69 MAGE A3 ASCI 69 EGFR HER2 69 ganetespib 69 CCX# 69 pharmacodynamic properties 69 SAR# [004] 69 CYT# potent vascular disrupting 69 mTOR inhibitors 69 HuMax EGFr 69 novel VDA molecule 68 Vitaxin 68 Virulizin ® 68 CA4P 68 metaglidasen 68 HGS ETR2 68 S/GSK# 68 nonclinical studies 68 tanespimycin 68 PS# [001] 68 #ME# 68 adecatumumab 68 INCB# [001] 68 favorable pharmacokinetic profile 68 liposomal formulation 68 ON #.Na 68 alvespimycin 68 AEG# 68 Ceflatonin 68 ENMD # 68 depsipeptide 68 enzastaurin 68 evaluating tivozanib 68 huC# DM4 68 pomalidomide 68 HE# [002] 67 mapatumumab 67 systemically administered 67 taxane resistant 67 mTOR inhibition 67 selective modulator 67 Traficet EN 67 mGluR2 NAM 67 HuLuc# 67 liposomal doxorubicin 67 radiation sensitizer 67 lintuzumab 67 anti leukemic 67 Trofex 67 seliciclib 67 demonstrated antitumor activity 67 Sym# 67 Elotuzumab 67 PSN# [002] 67 cediranib 67 gefitinib Iressa 67 androgen independent 67 CR# vcMMAE 67 tumor xenograft models 67 HGS ETR1 67 Panzem 67 axitinib 67 urocortin 2 67 orally administered inhibitor 67 XL# inhibits 67 Bezielle 67 uricase 66 secretory phospholipase A2 sPLA2 66 YONDELIS 66 Pralatrexate 66 MGd 66 xenograft models 66 cMET 66 riociguat 66 Panzem R NCD 66 induce apoptosis 66 anti fibrotic 66 CGEN # 66 vascular disrupting agent 66 Aurora kinase 66 Plicera 66 Xanafide 66 XmAb# 66 CDK inhibitor 66 #I TM# 66 samalizumab 66 OMP #M# 66 AEGR 66 Degarelix 66 Eg5 66 CBLC# 66 Safinamide 66 vidofludimus 66 PRT# 66 imatinib Gleevec ® 66 milatuzumab 66 CORT # 66 EGFr 66 PLX cells 66 decitabine 66 pan HDAC inhibitor 66 ZD# [001] 66 imetelstat 66 Tarceva TM 66 HER3 66 maximally tolerated dose 66 SYN# 66 antiangiogenic 66 velafermin 66 investigational monoclonal antibody 66 oral prodrug 66 pegylated liposomal doxorubicin 66 elacytarabine 66 SRT# [003] 66 ularitide 66 Preclinical studies 66 HIF PHI 66 Angiolix 66 IL #E 66 PKC# 66 pertuzumab 66 fosbretabulin 65 Omacetaxine 65 corticosteroid dexamethasone 65 mertansine 65 thalidomide Thalomid 65 Hsp# inhibition 65 docetaxel Taxotere ® 65 dacetuzumab 65 VEGF receptor 65 proteasome inhibitor 65 ISTODAX 65 RGB # 65 ALN TTR 65 Panzem R 65 histone deacetylase inhibitor 65 selective inhibition 65 CCR9 antagonist 65 vorinostat 65 receptor tyrosine kinase inhibitor 65 potent inhibition 65 PTHrP 65 ZOLINZA 65 protein tyrosine phosphatase 1B 65 ATL# [001] 65 DAVANAT 65 romidepsin 65 pharmacodynamic markers 65 anti CD3 65 PD LID 65 Imprime PGG 65 miR #a [001] 65 INGN 65 ALK inhibitor 65 ProSavin 65 targeting CD# 65 Clusterin 65 veltuzumab 65 ongoing Phase 1b 65 Aplidin 65 GRN#L 65 bortezomib Velcade ® 65 ARIKACE ™ 65 induces apoptosis 65 antiangiogenic agent 65 TACI Ig 65 EOquin TM 65 brivaracetam 65 HuMax CD4 65 FLT3 65 IAP inhibitor 65 #beta HSD1 65 ImmunoVEX HSV2 65 anticancer activity 65 eltrombopag 65 anticancer agent 65 Carfilzomib 65 anti EGFR antibody 65 MYDICAR ® 65 teriflunomide 65 castrate resistant prostate cancer 65 antibody MT# 65 EndoTAG TM -1 65 LRP5 65 glufosfamide 65 Sudhir Agrawal D.Phil 65 investigational humanized monoclonal antibody 65 CIMZIA ™ 65 interleukin IL -# 65 Kinoid 65 XL# XL# XL# 65 cilengitide 65 potent antitumor activity 65 leukemia AML 65 antitumor activity 65 PEGPH# 65 R roscovitine 65 CIMZIA TM 65 virus HCV protease inhibitor 65 preclinical efficacy 65 Archexin 65 TRAIL R1 65 paclitaxel Taxol 65 Vandetanib 65 dexpramipexole 65 PROSTVAC VF 65 antisense inhibition 65 rBChE 65 HGS ETR1 mapatumumab 65 PI3K Akt 65 histone deacetylase HDAC inhibitor 65 plasma kallikrein inhibitor 65 myeloproliferative diseases 65 JAK inhibitors 65 alpha#beta# integrin 65 PEG Interferon lambda 65 oral picoplatin 65 FGFR 65 Amrubicin 65 potent antiproliferative 65 Blinatumomab 64 Guanilib 64 angiogenesis inhibitor 64 microtubule targeting 64 cannabinor 64 mitogenic 64 Aflibercept 64 PROCHYMAL 64 Sapacitabine 64 TG# [003] 64 HCV protease 64 HQK 64 ISIS # 64 Aplidin R 64 HIF 1α 64 Onconase 64 goserelin 64 oral FTY# 64 MGCD# [001] 64 MAPK pathway 64 CD# expressing 64 mitotic kinesins 64 Zybrestat 64 Doxil ® 64 lymphoid malignancies 64 otelixizumab 64 chemopreventive agent 64 CYC# 64 JAK3 64 ALN VSP 64 alpha antagonist 64 LymphoStat B 64 Panzem NCD 64 LY# [003] 64 erlotinib Tarceva ® 64 AQ4N 64 dose proportionality 64 VitiGam 64 sorafenib Nexavar 64 antiangiogenic therapy 64 protein kinase inhibitor 64 VAPRISOL 64 FBPase 64 anti amnesic 64 sipuleucel T 64 plasma kallikrein 64 sPLA2 64 TLR7 64 BAY #-# 64 NV1FGF 64 generation antisense inhibitor 64 IRX 2 64 HIF 1a 64 inhibit metastasis 64 tumorigenicity 64 MET amplification 64 obatoclax 64 estramustine 64 PI3K/Akt pathway inhibitor 64 relapsed MM 64 galiximab 64 TMC# [002] 64 DXL# 64 Nanobody 64 fulvestrant 64 Chemophase 64 TLK# 64 myeloproliferative disorders 64 antiproliferative effects 64 antitumor efficacy 64 paricalcitol 64 tyrosine phosphorylation 64 PCK# 64 FK# 64 Seliciclib 64 GAMMAGARD 64 Enzastaurin 64 miR #a [002] 64 Gleevec resistant 64 masitinib 64 Capesaris 64 neratinib 64 Pemetrexed 64 glucagon receptor 64 thymalfasin 64 #D#C# 64 Telintra 64 pharmacodynamic effects 64 PRTX 64 Amplimexon 64 GRN# 64 tipifarnib 64 NGX# 64 transgene expression 64 atacicept 64 Tyrima 64 isoform selective 64 p# biomarker 64 lenalidomide Revlimid R 64 Serdaxin 64 forodesine 64 orally bioavailable 64 elotuzumab 64 leukemia CLL 64 tezampanel 64 Janus kinase 64 TNF α 64 neuroprotective properties 64 EpCAM 64 bicalutamide 64 hereditary deficiency 64 VEGF inhibitors 64 demethylating agents 64 CCR2 64 Vidaza azacitidine 64 5alpha reductase 64 R#/MEM # 64 JAK inhibitor 64 rhIGFBP 3 64 heparanase 64 pharmacodynamic profile 64 IL 1beta 64 eritoran 64 talabostat 64 Cutaneous T 64 CTLA 4 64 crizotinib PF # 64 HuMax CD# 64 Targretin 64 ANG# 64 Teriflunomide 64 Antitumor Activity 64 FOLOTYN ® 64 predictive biomarker 64 immunotoxin 64 NF kappaB activation 64 Kahalalide F 64 prostate carcinoma 64 TRAIL induced apoptosis 64 HIF 1alpha 64 ZFP TF 64 somatostatin analogue 64 schizophrenia CIAS 64 trastuzumab Herceptin 64 HER2 positive metastatic breast 63 anti CD3 antibody 63 Solorel TM 63 LT NS# 63 LY# [002] 63 Golimumab 63 CoFactor 63 immunoregulatory 63 JAK1 63 mouse xenograft models 63 cisplatin resistant 63 imatinib therapy 63 small molecule tyrosine 63 FOLFOX6 63 alpha folate receptor 63 sunitinib Sutent ® 63 Dasatinib 63 clusterin 63 Diffuse Large B 63 thyrotropin 63 ELACYT 63 Homspera 63 vascular disrupting 63 SCH # 63 5 HT2C receptor 63 Romidepsin 63 GFT# 63 receptor inhibitor 63 Insegia 63 TIMP 1 63 PlGF 63 pancreatic prostate 63 sodium glucose cotransporter 63 lumiliximab 63 OncoVEX GM CSF 63 bendamustine 63 trastuzumab Herceptin R 63 metastatic castration resistant 63 hA# 63 tarenflurbil 63 Tarvacin TM 63 RRM1 63 selective kinase inhibitor 63 c MYC 63 EGFR TKI 63 Tavocept 63 anti CTLA 63 BRAF inhibitor 63 tocilizumab 63 SERMs 63 OHR/AVR# 63 bevacizumab Avastin ® 63 TORISEL 63 Tarvacin 63 zanolimumab 63 splice variants 63 L BLP# 63 GSK# [001] 63 CYP#A# CYP#D# 63 Vidaza ® 63 HGS# 63 luteinizing hormone releasing 63 mycophenolate mofetil 63 GW# [003] 63 OvaRex R 63 HCD# [002] 63 nucleotide analog 63 Azixa 63 JAK2 inhibitor 63 serum phosphate 63 motesanib 63 CG# [003] 63 SPRYCEL ® 63 BNC# 63 Bendavia 63 interferon IFN 63 HERmark 63 PI3K/mTOR 63 metastatic malignant 63 DFMO 63 TOLAMBA 63 multicenter Phase II 63 TNFalpha 63 vivo potency 63 varespladib 63 sargramostim 63 Interferon alpha 63 IFN beta 63 TELINTRA 63 viral kinetics 63 solithromycin 63 GMX# 63 dasatinib Sprycel ® 63 Hsp# Inhibitor 63 cetuximab Erbitux R 63 rhIL 7 63 tafamidis 63 refractory chronic lymphocytic 63 castration resistant prostate cancer 63 novel anticancer 63 multiple myeloma MM 63 T#I [002] 63 docetaxel Taxotere R 63 Perifosine 63 experimental autoimmune encephalomyelitis 63 bortezomib Velcade 63 calcitriol 63 TELCYTA 63 florbetaben 63 Romiplostim 63 Thiovir 63 IFN α 63 Omacetaxine mepesuccinate 63 gemcitabine cisplatin 63 standard chemotherapy regimen 63 iSONEP 63 thromboxane A2 63 Tezampanel 63 docetaxel chemotherapy 63 thymidylate synthase TS 63 HER2 expression 63 CaPre TM 63 kidney urologic 63 administered subcutaneously 63 Epratuzumab 63 intratumoral injection 63 trastuzumab Herceptin ® 63 IFN alpha 63 NSCLC tumors 63 poly ADP ribose polymerase 63 ERK1 2 63 ADVEXIN 63 ASONEP 63 Phase Ib study 63 nab paclitaxel 63 Poly ICLC 63 zoledronate 63 trabectedin 63 ixabepilone 63 CD# CEA 63 flavopiridol 63 IL 1ß 63 eniluracil 63 KRAS mutations 63 cardioprotective effects 63 RAV# 63 alemtuzumab Campath 63 azacitidine 63 TRO# 63 Glufosfamide 63 cytoprotective 63 PNP inhibitor 63 Ophena 63 Valortim ® 63 hypoxia inducible factor 63 VELCADE melphalan 63 pemetrexed Alimta 63 ataluren 63 QT QTc 63 bexarotene 63 TLR antagonists 63 potent inhibitor 63 entinostat 63 ARIKACE 63 r hGH 63 Aliskiren 63 Immunohistochemical analysis 63 effector function 63 polycythemia vera PV 63 S#A# [002] 63 PEGylated anti 63 BRIM2 63 chemokine receptor 63 nilotinib 63 Bortezomib 63 CD# monoclonal antibody 63 HspE7 63 Phenoptin 63 antibody MAb 63 PPARgamma 63 Phase #/#a trial 63 selective androgen receptor modulator 63 antifibrotic 63 CD# antibody [001] 63 delafloxacin 63 beta interferons 63 alefacept 63 PDE4 inhibitor 62 cisplatin gemcitabine 62 FOLFOX6 chemotherapy regimen 62 Posiphen 62 MyVax R 62 pain palliation 62 T#I mutant 62 potently inhibited 62 vascular disrupting agents 62 androgen receptor AR 62 vivo validation 62 heavily pretreated 62 Myelodysplastic Syndrome MDS 62 inhaled iloprost 62 pro angiogenic 62 Darapladib 62 GAP #B# 62 Ophena TM 62 ERK pathway 62 Xelox 62 ADI PEG 62 PROSTVAC TM 62 Subgroup analysis 62 SERCA2a 62 nucleoside analog 62 COPEGUS 62 MEK inhibitors 62 NEUGENE 62 pharmacokinetic equivalence 62 Annamycin 62 NEUMUNE 62 oral JAK1 62 IGFBP 3 62 hyperphenylalaninemia HPA due 62 lymphoma subtypes 62 Mipomersen 62 MEK inhibitor 62 Phase 1b trial 62 A3 adenosine receptor 62 insulin degludec 62 Pimavanserin 62 Asentar 62 VEGFR2 62 gemcitabine Gemzar ® 62 cytokine interleukin 62 potent anticancer 62 chemoresistant 62 pharmacodynamic 62 p# activation 62 thrombin receptor 62 omega interferon 62 Cloretazine R 62 chemotherapy induced neutropenia 62 nutlin 3a 62 bardoxolone methyl 62 compound AEZS 62 INCB# [002] 62 STRIDE PD 62 EGFR inhibition 62 Dacogen decitabine 62 IGF 1R 62 triphendiol 62 ADAGIO study 62 PTP 1B 62 lactate dehydrogenase LDH 62 immunostimulatory 62 panitumumab Vectibix 62 EZN 62 sorafenib tablets 62 sCD# 62 lesinurad 62 rFVIIa 62 EGFR pathway 62 HSP# inhibitor 62 Hedgehog pathway 62 GPIIb IIIa 62 OvaRex ® MAb 62 immunomodulating 62 erythropoietic 62 MEK inhibitor RDEA# 62 gemcitabine Gemzar 62 AMD# [003] 62 neuroregenerative 62 intranasal delivery 62 imatinib Gleevec 62 vitro cytotoxicity 62 Lp PLA 2 62 Janus Kinase 62 EGFR receptor 62 novel peptide 62 MabCampath 62 KNS # 62 4E BP1 62 soluble tumor necrosis 62 GVAX ® 62 interleukin IL 62 antiapoptotic 62 pharmacodynamic profiles 62 HMG CoA reductase inhibitors 62 Reolysin 62 Davanat 62 humanized anti 62 sunitinib Sutent 62 potent topoisomerase II 62 HCV protease inhibitors 62 EndoTAGTM 1 62 Epidermal Growth Factor Receptor 62 calcitonin 62 antitumour activity 62 telaprevir dosed 62 perifosine 62 RhuDex ® 62 rFIXFc 62 cytokines IL 62 lucinactant 62 GHRH 62 RLY# 62 pralatrexate 62 EGFRvIII 62 generation purine nucleoside 62 PKCi 62 immunomodulation 62 Arranon 62 Phase 2a trial 62 castration resistant 62 cyclooxygenase 62 HCV replicon 62 TLR9 agonists 62 TNF Tumor Necrosis Factor 62 EGF receptor 62 pathophysiological effects 62 tubulin polymerization 62 velafermin belinostat 62 gastrin 62 HIF PH inhibitors 62 cobiprostone 62 relapsed multiple myeloma 62 immunomodulatory 62 Lisofylline 62 Virulizin R 62 pDCs 62 prostate cancer AIPC 62 eprotirome 62 XL# anticancer compounds 62 Resten NG 62 deforolimus 62 Protein Kinase C 62 pharmacokinetic interactions 62 IgG1 antibody 62 epithelial tumors 62 Fibrillex TM 62 cardiac toxicity 62 WT1 62 activin 62 PEG IFN 62 etanercept Enbrel 62 recurrent glioblastoma multiforme 62 myeloproliferative 62 partial agonist 62 dasatinib Sprycel 62 GRNVAC1 62 lintuzumab SGN 62 sodium thiosulfate STS 62 davunetide intranasal AL 62 mg kg dose 62 2 methoxyestradiol 62 fibrotic disease 62 selectively inhibited 62 interferon γ 62 TAp# 62 pleiotropic 62 IMiDs 62 adriamycin 62 iNOS 62 V#F mutation 62 immune modulatory 62 PPARγ 62 mRCC 62 refractory acute myeloid 62 immune modulation 62 Factor VIIa 62 inhibitor RG# 62 antitumor 62 mitogen activated ERK kinase 62 PEGylated interferon beta 1a 62 NS#/#A protease 62 phase IIa clinical 62 tumor antigen 62 sphingosine kinase 62 safinamide 62 CCR5 antagonist 62 Muraglitazar 62 XL# [003] 62 ATL/TV# 62 cytokine refractory 62 teduglutide 62 CEQ# 62 PSN# [001] 62 TBC# 62 IGFBP2 62 Cloretazine R VNP#M 62 osteogenic 62 GAMMAGARD LIQUID 62 targeted antifolate 62 Darinaparsin 62 lactate dehydrogenase 62 PROMACTA 62 Interferon beta 62 cis retinoic acid 62 HER2 overexpression 62 seropositive patients 62 humanized monoclonal antibodies 62 idraparinux 62 XP# Transported Prodrug 62 phase IIb trial 62 refractory multiple myeloma 62 MCSP respectively 62 blinatumomab 62 plasma pharmacokinetics 62 KRAS wild 62 oral Xeloda 62 TroVax ® 62 Gemzar ® 62 NF kB pathway 62 bleomycin 62 radezolid 62 phosphate S1P 62 ZACTIMA 62 metastatic hormone refractory 62 Allovectin 7 ® 62 bevacizumab Avastin R 62 IL 1Ra 62 midstage clinical 62 anti angiogenic agents 62 CINQUIL 62 adecatumumab MT# 62 Granulocyte Colony Stimulating Factor 62 G#DT 62 SPC# [001] 62 fusion enhancers 62 IFN γ 62 Debio 62 low dose cytarabine 62 IGF 1R inhibitor 62 NPH insulin 62 TREANDA 62 Vidofludimus 61 Refractory Hodgkin Lymphoma 61 PDE#A 61 nitazoxanide 61 inhibiting COX 61 AAG geldanamycin analog 61 pancreatic colon 61 MUC1 61 idarubicin 61 antiproliferative activity 61 retaspimycin 61 matrix metalloproteinases 61 posaconazole 61 Abiraterone acetate 61 aurora kinase 61 TKM ApoB 61 ELND# 61 inhibit KSP 61 gamma secretase inhibitor 61 FOLFOX chemotherapy 61 small molecule Hedgehog 61 antiviral efficacy 61 colorectal carcinoma 61 REOLYSIN ® 61 Trastuzumab 61 sapacitabine 61 Interferon Beta 61 neurologic progression 61 Xcellerated T Cells 61 Valortim 61 APTIVUS r 61 LymphoStat B TM 61 BiTE antibodies 61 PDGFR 61 Revimmune 61 weekly subcutaneous injections 61 MAbs targeting 61 olaparib 61 PGE2 61 AP# [003] 61 multikinase inhibitor 61 preclinical studies 61 neurite outgrowth 61 TNFa 61 lapatinib Tykerb 61 Pegylated 61 THR beta agonist 61 Akt activation 61 basal bolus regimen 61 Thiarabine 61 Novel Oral 61 NFkappaB 61 Decitabine 61 valopicitabine 61 CRLX# 61 microglial activation 61 BMS# 61 epigenetic therapies 61 kinase inhibition 61 fluoropyrimidine 61 murine model 61 pharmacological chaperone 61 myocardial necrosis 61 tyrosine kinase inhibitor 61 potent anti angiogenic 61 SIRT2 61 tubulin inhibitor 61 recurrent NSCLC 61 Dapagliflozin 61 reslizumab 61 apoptosis proteins 61 MYCN amplification 61 antitumor effects 61 P#X# 61 busulfan 61 KRN# 61 LHRH antagonists 61 HDAC inhibition 61 JAK#/JAK# 61 thetreatment 61 isoenzyme 61 hoFH 61 optimal dosing regimens 61 anthracycline chemotherapy 61 ALN TTR# 61 Panitumumab 61 vitro experiments 61 Phase 2b Clinical Trial 61 NLX P# 61 AACR NCI EORTC 61 recurrent glioblastoma 61 belinostat 61 subcutaneous SC 61 therapeutic monoclonal antibody 61 inhibiting telomerase 61 Copegus ribavirin 61 rFVIIIFc 61 NEVO ™ 61 prostate cancer CRPC 61 targeted radiotherapeutic 61 HAAH 61 TTR gene 61 Upregulation 61 XL# XL# 61 pDC 61 papillary renal cell carcinoma 61 somatostatin 61 CCR9 61 Viramidine 61 novel topoisomerase 61 Aclidinium 61 SB# ONX 61 renoprotective 61 immune modulator 61 CDK inhibitors 61 factor G CSF 61 EndoTAG TM 61 amrubicin 61 CLORETAZINE TM VNP#M 61 prostanoid 61 huN# DM1 61 neuroprotectant 61 oral ridaforolimus 61 myelofibrosis polycythemia vera 61 DU #b 61 sitaxsentan 61 fluvastatin 61 Phase Ib clinical 61 replicon 61 IGF IR 61 interferon gamma 1b 61 IgG1 monoclonal antibody 61 medically inoperable 61 peptide antigens 61 mTOR inhibitor 61 nalbuphine ER 61 relapsed refractory multiple myeloma 61 Forodesine HCl 61 Lupuzor ™ 61 LHRH agonists 61 Vilazodone 61 neointimal hyperplasia 61 tramiprosate Alzhemed TM 61 FOLFIRI 61 SIRT1 activators 61 oral rivaroxaban 61 Saxagliptin 61 R#/MEM 61 syngeneic 61 Exelixis compounds 61 mineralocorticoid receptor 61 EGFR tyrosine kinase inhibitors 61 orally dosed 61 visilizumab 61 mCRC patients 61 HDAC Inhibitor 61 phase Ib 61 ERK signaling 61 interferon lambda 61 lymphomas leukemias 61 SNT MC# 61 Genentech Rituxan 61 LymphoStat B belimumab 61 Arimoclomol 61 anticancer therapies 61 apremilast 61 dose cohort 61 complete cytogenetic response 61 small molecule activators 61 IMA# 61 PDX pralatrexate 61 lenalidomide dexamethasone 61 achieved statistical significance 61 Doxil 61 alkylating agent 61 p# MAPK 61 pharmacokinetic parameters 61 gonadotrophin releasing hormone GnRH 61 adalimumab Humira 61 xenograft tumors 61 rNAPc2 61 Pharmacokinetic analyzes 61 sunitinib malate 61 plasma renin activity 61 Azilect ® 61 dosage regimens 61 chemotherapeutic drug 61 BCX#

Back to home page